Approaches to treatment of HIV facial lipoatrophy.
HIV-associated facial lipoatrophy has become epidemic among the greater than 1 million HIV-infected individuals living in the United States. Those affected usually have well-controlled HIV disease, and are most often healthy and living productive lives. However, their facial appearance often suggests the opposite and frequently serves as a stigma and psychological burden. Treatment approaches may be divided into three categories: 1) Surgically placed alloplastic, autologous, or synthetic implants; 2) Injection of temporary fillers; 3) Injection of permanent fillers, including liquid injectable silicone. Salient aspects of each treatment are reviewed, along with new techniques and pearls on the correct use of liquid injectable silicone.
Jones
D
D
Division of Dermatology, University of California at Los Angeles, Los Angeles, CA, USA.
D044966:Anti-Retroviral Agents / Q000009:adverse effects; D005145:Face / Q000473:pathology / Q000601:surgery*; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000601:surgery*; D006801:Humans; D007279:Injections, Subcutaneous; D015187:Lipectomy; D019736:Prostheses and Implants; D012307:Risk Factors; D020034:Silicone Gels
D044966:Anti-Retroviral Agents; D020034:Silicone Gels